Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing (GenesinJIA)
Juvenile idiopathic arthritis (JIA) is considered to be a multifactorial disease caused by a combination of environmental factors and predisposing genetic factors. Twins studies found a strong heritability (strong genetic factors) but genetic studies such association studies of large cohorts of patient (GWAS or Genome Wide Association Study) have elucidated less than 20 % of the genetic basis of JIA. The vision of the genetics of multifactorial diseases has recently changed revealing a large clinical and genetic heterogeneity of these diseases. Indeed, the advent of next-generation sequencing identified non-multifactorial genetic hereditary disease related to mutations in genes having strong effect on the onset of the disease without real impact of environmental factors among the so called "multifactorial diseases" (Parkinson's, diabetes, osteoarthritis, Alzheimer's, hypertension ...)The investigators propose to study 30 families with several forms of JIA by next-generation sequencing. Identifying the genetic basis of JIA in these families will help to better understand the physiopathology of this disease and may help to the identification of novel therapeutic targets for other patients with JIA.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing|
- Identification of new genes by Next Generation Squencing (NGS) [ Time Frame: 1 day ] [ Designated as safety issue: No ]Identification of new genes by Next Generation Squencing (NGS) in order to propose a new classification for prognosis and therapeutic orientation
|Study Start Date:||March 2014|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
No Intervention: Juvenile idiopathic arthritis.
Biological: Blood sample
Please refer to this study by its ClinicalTrials.gov identifier: NCT02067962
|Principal Investigator:||David DG GENEVIEVE, PU-PH||Montpellier university hospital|